NBY vs TXT · $51.9M cap vs P/E 19, rev $7.52B
NovaBay Pharmaceuticals Inc (NBY) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
NovaBay Pharmaceuticals Inc (NBY) is a biotechnology company listed on US.
Textron Inc (TXT) is a aerospace & defense company listed on US.
NBY does not have a complete income-statement cache yet.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
NBY currently screens at market cap $51.9M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the NBY and TXT stock pages for the full models.
Not investment advice.